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Abstract
Background: Having reliable forecasts is critical now for producers, malaria-endemic countries
and agencies in order to adapt production and procurement of the artemisinin-based combination
treatments (ACTs), the new first-line treatments of malaria. There is no ideal method to quantify
drug requirements for malaria. Morbidity data give uncertain estimations. This study uses drug
consumption to provide elements to help estimate quantities and financial requirements of ACTs.
Methods:  The consumption of chloroquine, sulphadoxine/pyrimethamine and quinine both
through the private and public sector was assessed in five sub-Saharan Africa countries with
different epidemiological patterns (Senegal, Rwanda, Tanzania, Malawi, Zimbabwe). From these
data the number of adult treatments per capita was calculated and the volumes and financial
implications derived for the whole of Africa.
Results:  Identifying and obtaining data from the private sector was difficult. The quality of
information on drug supply and distribution in countries must be improved. The number of adult
treatments per capita and per year in the five countries ranged from 0.18 to 0.50. Current adult
treatment prices for ACTs range US$ 1–1.8. Taking the upper range for both volumes and costs,
the highest number of adult treatments consumed for Africa was estimated at 314.5 million,
corresponding to an overall maximum annual need for financing ACT procurement of US$ 566.1
million. In reality, both the number of cases treated and the cost of treatment are likely to be lower
(projections for the lowest consumption estimate with the least expensive ACT would require US
$ 113 million per annum).
There were substantial variations in the market share between public and private sources among
these countries (the public sector share ranging from 98% in Rwanda to 33% in Tanzania).
Conclusion: Additional studies are required to build a more robust methodology, and to assess
current consumptions more accurately in order to better quantify volumes and finances for
production and procurement of ACTs.
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Background
Reliable forecasts for antimalarial treatments require-
ments become particularly urgent now that malaria
endemic countries are changing their treatment policies
and adopting artemisinin-based combination therapies
(ACTs) following WHO recommendations [1]. Coverage
so far has been low for a variety of reasons, including the
lack of reliable forecasts of antimalarial drug volumes
needed for both global and local consumption.
More accurate forecasts are, therefore, needed both at the
producer's and the customer's end (at country and inter-
national level) in order to harmonize supply and
demand.
Both morbidity and consumption methods of quantifica-
tion have limitations, but can be complementary. Mor-
bidity-based estimations of drug requirements do not take
into account the actual consumption, which results from
drug availability and access, customer's willingness to pay
(which largely depends on the treatment price to the end
user) and current practice to treat fever (as opposed to par-
asitologically confirmed malaria) with antimalarial drugs
(some 2.84 billion fever episodes would occur annually in
Africa [2]). While this latter practice leads to significant
over-treatment and wastage, weaknesses in the systems
result in the failure to reach patients who do have malaria
and need treatment.
Health information systems are insufficient to quantify
the requirements for antimalarials [3]. Estimates of the
malaria burden vary greatly with the methodology used
and assumptions made from 215 to 374 million [4] in
Africa (~70% of all cases of falciparum malaria world-
wide). To complement malaria morbidity-based forecasts
this study used a consumption approach to produce fore-
casts of volumes (primarily for drug manufacturers and
procurement agencies) and financial requirements (of pri-
mary interest for donors and governments). In the
absence of a standard methodology, five African countries
representing diverse geographical and epidemiological
settings were selected, and then projections were made
based on the data obtained to the whole of Africa, estimat-
ing lower and upper levels of consumption.
Methods
The analysis was limited to first-line drugs in use based on
the treatment guidelines at the time of the study, essen-
tially chloroquine and sulphadoxine/pyrimethamine for
uncomplicated malaria, and quinine for more severe
malaria. A treatment policy change occurred only in
Rwanda during the observation period and was taken into
account [5].
Representative countries of the main geographical and cli-
matic regions (Southern, Eastern, Central, and Western
Africa) were selected, with different endemicities, health
systems (relative importance of public and private sector),
and treatment-seeking behaviours.
Data were collected in 2003 in Rwanda (Central Africa),
Senegal (Western Africa), Tanzania (Eastern Africa),
Malawi and Zimbabwe (Southern Africa). The study cov-
ered the period 1999–2002. Data were available for the
whole period for Malawi and Zimbabwe, while for
Rwanda complete information, including the private sec-
tor, was available for 2001 and 2002. Data from Senegal
were available only for the year 2000 for the public sector,
and 2002 for the private sector. For Tanzania, calculations
were based on 2000 and 2001 data.
Data were collected through visits, interviews of people in
charge of supply or distribution, inspection of internal
documents (e.g. distribution list of public central medical
stores, list of imports of private wholesalers), source veri-
fication, assisted by national and international consult-
ants for this specific study. Both the public and private
sectors were investigated. The informal sector was not
analysed systematically.
More specifically, imports, sales or deliveries of the agen-
cies importing antimalarial medicines were evaluated.
In the public sector, investigations concerned the central
medical store (or equivalent), the public services which
procure or receive antimalarial drugs directly (e.g.
National Malaria Control Programme), and international
organizations which might be involved in the procure-
ment or donation of antimalarial drugs. The semi-public
sector (private non-profit and faith-based organizations)
was considered also as part of the public sector. For the
private commercial sector, all the local wholesalers were
contacted (or, if too many, the main ones, targeting 80%
of the turnover).
Production from domestic manufacturers was also taken
into account if aimed for the domestic market, unless
already accounted for in the estimates from public and
private sectors.
All these agencies and companies were identified in col-
laboration with the national public health and pharma-
ceutical authorities, and a list of the organizations to be
visited was further prepared. The market share of the sur-
veyed organizations in the private and the public sector
was estimated through the analysis at the national level of
import data, pharmacy council data and interviews of
local officials and experts. When the turnover estimate
was below 100% because of non-responders, a post-hocMalaria Journal 2007, 6:91 http://www.malariajournal.com/content/6/1/91
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extrapolation was made in order to estimate the total
demand in each sector.
For each identified drug, the consumption was studied for
all dosages and forms on the market: adult and paediatric
dosages, oral (solid and syrups) and injectable forms.
International Non-proprietary Names (INN) were used
instead of brand names.
Data were collected first about the smallest pharmaceuti-
cal unit. They were then aggregated by pharmaceutical
form for each drug, subsequently by drug, then by sector,
and finally by country.
All quantities, including paediatric tablets, were trans-
formed into equivalent adult treatments. The conversion
formulas used were based on the WHO recommended
adult malaria treatment course [6]. Syrup formulations
and injectable formulations were not converted to equiv-
alent adult treatment courses, but this has a negligible
impact on overall volumes. It was not possible to separate
use for treatment and prophylaxis, but the latter repre-
sents a marginal part of the consumption in studied coun-
tries according to information collected within national
malaria programmes (especially at the time when data
were collected). For injectable drugs, the indicator was the
quantity of ampoules required for a one-day adult treat-
ment.
Consumption was systematically annualized in each
country. Indeed, in the public sector, distribution to
peripheral stores was most often recorded monthly, while
supply was done much less frequently (e.g. through ten-
ders). In the private sector imports are more frequent than
in the public sector, which allowed calculating monthly
mean evaluations of imports, before annualizing.
The number of oral treatments of malaria consumed in
Africa were projected based on the general population
data and forecasts for the continent [7], together with the
data on percentage of population at malaria risk [8]. The
population at risk was calculated in Africa for 2004. Based
on available figures, people at risk of endemic and epi-
demic malaria were calculated at 566,283,000 in 2000,
and 629,030,000 in 2004. The estimated population at
risk for the whole of Africa was then multiplied by the
upper and lower figures of the consumption of antimalar-
ial medicines (expressed by the ratio of adult treatment
per capita), in order to estimate the range of global con-
sumption.
Results
Sources of information identified
Identifying and obtaining data from the formal private
sector was difficult. A centralized system tracing products
provided through both the public and the private sector
did not exist in the study countries. National health
authorities had scanty information on importers and dis-
tributors for the private sector. Equally incomplete were
data on imported medicines, which, when available, were
aggregates of different compounds, presentations and
trade names, lumped together to express value of goods.
Table 1 shows the number of organizations visited in the
private and the public sector in each country, as well as
their estimated market share.
Private importers and distributors were disinclined to
share information about sales, but less reluctant to dis-
close import data. In contrast, the public sector, including
not-for-profit organizations, was considerably more
receptive and > 80% of the turnover of this sector was cap-
tured.
In general, one can be reasonably confident in the data
gathered in Malawi and Zimbabwe (data collected for
1999–2002) as well as Rwanda (complete information,
including private sector, for 2001 and 2002). Data from
Senegal were more fragmentary, but these figures were in
good agreement with another study by Management Sci-
ence for Health for 2002 [9]. Reliable data were available
for the year 2000 for public services, while for 2002, data
were obtained only for two companies in the private sec-
tor (and incomplete data were to be extrapolated for one
of them). In Tanzania calculations were based on the
years 2000 and 2001, which were more reliable for public
Table 1: Informants visited.
Country Malawi Rwanda Senegal Tanzania Zimbabwe
Informants private public private public private public private public private public
Importers contacted 7 2 1 2 3 21 41 8 1
Importers providing data 6212328181
Importers declining 1000003000
Estimated % of market 80% 100% 90% 100% >80% 100% <50% 100% 80% 100%
Manufacturers visited 20211
Estimated % of market 100% n.a. 100% 100% 100%Malaria Journal 2007, 6:91 http://www.malariajournal.com/content/6/1/91
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services. Confidence in the figures there is lower than for
the other countries due to the large number of private
importers, their rather low level of response, and the lack
of correlation between their figures and those from the
pharmacy board.
Besides the collection of data itself, potential biases in the
methodology might originate from other external factors
affecting consumption: changes in both the economic and
epidemiological patterns influence private and public
demand, which was partly minimized by collecting data
over several years. Changes in prices of drugs or user-fee
system can also affect the results. However, none of them
appeared to be significant during the period.
General findings on consumptions
Table 2 shows the number of solid form oral adult treat-
ments consumed per year and provided by both the pub-
lic and private sectors during the observation period in
each country with respect to the population of the country
in 2001 [10].
In order to compare countries and to extrapolate results to
other countries in the continent, the ratio of adult treat-
ment equivalents to the overall population was calculated
at between 0.18 and 0.50. The resulting figures in terms of
total and per-capita number of adult treatments equiva-
lents are somehow consistent with the WHO estimated
number of cases in those countries [11].
Market share of antimalarial medicines in the private and 
public sector
Figure 1 shows the proportion of antimalarial oral treat-
ments (except syrups) distributed and sold through the
public and the private sector in each country. Tablets rep-
resent the vast majority of the antimalarials distributed or
sold. Drug supplies by public institutions are dominant in
Rwanda (>90%), Senegal (>80%), high in Malawi (ca.
60% on average over four years), and much lower in Zim-
babwe (38%) and Tanzania (33%).
By contrast, syrups, which are more expensive, and repre-
sent a very small proportion of the total treatments are
essentially sold through the private sector (Table 3). For
both syrup and injectable formulations there was signifi-
cant inter-country variation (highest consumption in Sen-
egal and Tanzania). In Senegal the public sector had the
largest share of the supplies of injectable treatments
(78%), which was related to the prevailing practice of
treating uncomplicated malaria with injectable quinine in
that country.
Estimation of requirements for antimalarial medicines in 
Africa
As stated in the methods section, circa. 629 million were
estimated to be at risk of malaria in Africa in 2004. When
applying the lower (0.18) and upper (0.50) rates of con-
sumption to this overall population (Table 2), the global
consumption of antimalarials in Africa can be estimated
in the range of 113 to 314.5 million adult treatments.
Current prices of an ACT adult treatment adopted in Afri-
can countries vary between US$ 1 (artesunate+amodi-
aquine, Sanofi-Aventis), and US$ 1.8
(artemether+lumefantrine, Novartis) for public or not-
for-profit organizations.
Together, these data lead to an overall yearly financial
requirements between US $ 113 million (lower consump-
tion estimate with cheaper ACT) and 566.1 million
(higher consumption estimate with most expensive ACT)
if the same levels of consumption for chloroquine and
sulphadoxine/pyrimethamine apply to ACTs.
Country percentage share by public sector of antimalarial  treatments over the period under study Figure 1
Country percentage share by public sector of antimalarial 
treatments over the period under study.
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Table 2: Solid form oral treatments yearly consumed in each country (public and private sector).
Country Malawi Rwanda Senegal Tanzania Zimbabwe
Population (millions) [Ref 10] 11,8 8,4 10,6 35,5 12,7
Calculated number of adult treatments equivalents (millions) 4,6 1,5 5,3 15 5,4
Calculated adult treatments equivalents per capita 0,39 0,18 0,50 0,42 0,43
Estimated number of malaria cases (million) [Ref 11] 5,5 1,2 4,3 14,5 4Malaria Journal 2007, 6:91 http://www.malariajournal.com/content/6/1/91
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Discussion
The aim of this study was to generate simple, locally col-
lected information to help estimate antimalarial drugs
consumption (as orders of magnitude as opposed to accu-
rate estimates) in the recent past in Africa. Malaria treat-
ment policies have changed from monotherapies (used
when this study was conducted) to artemisinin-based
combination therapies (ACTs) as now recommended by
the World Health Organization (WHO) [1,12,13]. So far,
lack of reliable data to quantify demand, compounded
with the challenges of changing policy and practice, con-
tribute to the current failure to deploy ACTs at the levels
required. As a consequence supplies are not adapted and
adequate funding for procurement cannot be planned.
This study was done in order to help inform production
and procurement of ACTs of potential future demand as
well as projecting the corresponding financial require-
ments based on cost of drugs, while acknowledging that
other costs are also involved in policy change. The study
has methodological limitations.
In the first place, consumption methods are better suited
when current policies and patterns continue unchanged,
which is not the present case : ACTs, possibly after parasi-
tological confirmation, are to replace monotherapies
taken on clinical ground. Here, in order to complement
equally questionable morbidity-based data, consumption
generates information based on the number of fever epi-
sodes actually treated with antimalarials, whether true
malaria cases or not. The consequences on the introduc-
tion of ACTs on consumption are difficult to predict. A
wider use of rapid diagnostic tests will likely affect con-
sumption. ACTs are more effective but also more expen-
sive than traditional monotherapies. In the short term
their cost and limited supplies will hold back scaling-up.
Their efficacy may, in the medium term, generate
increased demand but in the longer term reduce morbid-
ity, though the effect will largely depend on intensity of
transmission.
Another issue is that the choice of study countries was
based on epidemiological and not statistical criteria. In
addition, the calculations made assumed the price to the
end user to be the same of former first-line single-agent
treatments, while this may be very different depending on
whether ACT will be subsidized or not and to what extent.
A case has been made for ACTs to be subsidized [14]. Fur-
thermore, tracking data is inherently difficult within the
current system in both the private and public sector, and
this is obviously reflected in this study. For instance,
detailed information on sales could not be obtained by
private importers and distributors essentially because they
feared this could be used against them either by the fiscal
administration or competitors.
Finally, the informal sector was not specifically investi-
gated. However, using official drug imports into the coun-
try should account for it as well, as these retailers generally
obtain their medicines from private wholesalers, private
pharmacies, or even public services. One must acknowl-
edge though that variable amounts of drugs may enter
countries illegally, and this obviously cannot be
accounted for.
The fact that extrapolations generated with a consump-
tion approach match and support morbidity-based esti-
mates [4] may be a mere coincidence as the two methods
measure different variables: the number of cases that
should ideally be treated on the one hand, and the
number of treatments used on the other hand.
The other component of this research was financial
requirements. While other costs are obviously involved
for countries when shifting to ACTs, we have chosen to
concentrate on the costs of drugs as the major financial
burden. ACTs are more expensive than the traditional
antimalarial drugs, and the question is how this will affect
penetration and coverage.
This approach estimates financial requirements to range
between US $ 113 million (lower consumption estimate
with an ACT at US $ 1 per adult treatment) and 566.1 mil-
lion (higher consumption estimate with an ACT at US $
1.8 per adult treatment) if the same levels of consumption
for chloroquine and sulphadoxine/pyrimethamine apply
to ACTs. While this range is very wide, it provides finan-
cial brackets which are for instance within reach of inter-
Table 3: Yearly volumes of syrups and injectables, with public and private sectors market shares.
country Malawi Rwanda Senegal Tanzania Zimbabwe
Number of syrups (units) 2,750 5,500 295,000 561,000 53,500
Syrups/total adult treatments <0.1% 0.4% 5.5% 3.7% 1%
% sales by private sector 50% 50% 84% 100% 80%
Injectables (1 day treatment equivalents) 26,000 30,000 954,000 1,000,000 16,000
% sales by private sector 60% 50% 22% 75% 100%Malaria Journal 2007, 6:91 http://www.malariajournal.com/content/6/1/91
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national donor support. In comparison, it was estimated
that US$ 70 billion were disbursed in official develop-
ment programmes in 2003 by OECD member states [15].
The next question is by whom these costs will be incurred
or covered. This study found a substantial (yet variable)
market share of the public sector, which was at odds with
the 20% commonly cited for Africa [16-18]. There are sev-
eral unresolved methodological issues with the collection
and interpretation of data on treatment-seeking behav-
iour which make inference on the drug supplier (private
or public) difficult: self-treatment, home treatment, com-
munity treatment, treatment by a health professional, are
not clearly defined categories and multiple sourcing of
treatments is possible. While differences in health-seeking
behaviours [19] may contribute to these variations, a
plausible explanation is that market shares are usually
expressed in financial terms (value of medicines), which
tends to overestimate the proportion of drugs supplied
through the private market that generally would charge
higher unit costs, while here volumes were used instead.
Conclusion
There were situations in which it was difficult to retrieve
and extract information. Countries should improve the
quality of information on drug supply and distribution.
Better monitoring of the national demand and market
will benefit policy makers in order to adapt choices,
improve follow up and increase access. Diversity of usage
across countries should be considered to adapt projec-
tions and interventions.
The results of this study provide information on brackets
of volumes and finances for ACTs. Since deployment will
be staggered, demand and investments will be more likely
to start at the lower end of the spectrum.
The approach used to generate these data should be fur-
ther tested for its applicability, limitations and robustness
in order to further refine it and to assess current consump-
tions more accurately across Africa.
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